정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1360 | Withdrawn | Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19) | Covid19 | Drug: Fluoxetine Drug: Placebo |
Early Phase 1 | Milton S. Hershey Medical Center | OTHER | 0 | All | 18 Years | Milton S. Hershey Medical Center Clinical Research Center, Hershey, Pennsylvania, United States |
| 1359 | Recruiting | Fluoxetine to Reduce Intubation and Death After COVID19 Infection | Cytokine Storm | Drug: Fluoxetine | Phase 4 | University of Toledo Health Science Campus | OTHER | 2000 | All | 18 Years | University of Toledo, Toledo, Ohio, United States |
| 1358 | Recruiting | FLuticasone in cOvid Treatment (FLOT) | Covid19 | Drug: Fluticasone Propionate | Phase 3 | University of Medicine and Pharmacy at Ho Chi Minh City | OTHER | 500 | All | 18 Years | University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam |
| 1357 | Recruiting | Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients | Covid19 | Drug: Placebo Drug: Fluvoxamine |
Phase 2 | SigmaDrugs Research Ltd. | INDUSTRY | 100 | All | 18 Years ~ 70 Years | Del-pesti Centrumkorhaz, Budapest, Hungary Semmelweis Egyetem Pulmonologiai Klinika, Budapest, Hungary Orszagos Koranyi Pulmonologiai Intezet, Budapest, Hungary Debreceni Egyetem Kenezy Gyula Korhaz Infektologia, Debrecen, Hungary |
| 1356 | Suspended | Fluvoxamine for Adults With Mild to Moderate COVID-19 | Mild to Moderate COVID-19 | Drug: Fluvoxamine Drug: Placebo |
Phase 2 | Asan Medical Center | OTHER | 400 | All | 18 Years ~ 85 Years | Asan Medical Center, Seoul, Korea, Republic of |
| 1355 | Active, not recruiting | Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) | Coronavirus | Drug: Fluvoxamine Drug: Placebo |
Phase 3 | Washington University School of Medicine, Covid-19 Early Treatment Fund, McGill University Health Centre Department of Medicine Clinical Practice Assessment Unit, Cures Within Reach | OTHER | 1100 | All | 30 Years | Northwestern University, Chicago, Illinois, United States Washington University School of Medicine, Saint Louis, Missouri, United States University of Utah, Salt Lake City, Utah, United States Fred Hutchinson, Seattle, Washington, United States McGill University Health Center, Montreal, Quebec, Canada |
| 1354 | Completed | Fostamatinib for Hospitalized Adults With COVID-19 | Coronavirus Disease 2019 | Drug: Placebo Drug: fostamatinib |
Phase 2 | National Heart, Lung, and Blood Institute (NHLBI) | NIH | 62 | All | 18 Years | National Institutes of Health Clinical Center, Bethesda, Maryland, United States INOVA Health Systems, Falls Church, Virginia, United States |